Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia

Gater, Adam; Heron, Louise; Abetz-Webb, Linda; Coombs, John; Simmons, Jeff; Guilhot, Joëlle; Réa, Delphine

doi:10.1016/j.leukres.2012.01.021

Cited by 58 publications

(63 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Measuring treatment adherence is difficult, and several methods have been carried out from self-reported adherence to electronic devices, including prescription refill analysis [4,5]. However, although the former probably overestimates the actual adherence, it has the advantage of being easily undertaken in routine practice with minimal costs.…”

Section: Discussionmentioning

confidence: 99%

Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies

et al. 2014

View full text Add to dashboard Cite

Objectives: Patient adherence is a challenge in oncology and hematology practice. Hormone therapy data in breast cancer suggest insufficient adherence and poor persistence. Limited data are available for targeted therapies (TT) including tyrosine kinase and mammalian target of rapamycin inhibitors. Methods: We performed a prospective survey using a 15-item questionnaire in patients with solid tumors and hematologic malignancies receiving oral anticancer therapy. Treatment duration, setting (adjuvant vs. metastatic), cancer type, age, and comedication were recorded. Results: 201 patients (median age 65.5 years) participated, 102 with TT and 99 with hormone therapy or chemotherapy (HC). The median time of drug intake was 11.0 months. Written information was more frequently given to TT patients (68.6 vs. 23.2%, p < 0.0001). TT and HC patients showed equal adherence to therapy (72.5 vs. 69.6%, p = n.s.) despite TT patients experiencing more side effects (p < 0.0001) and taking more concomitant oral medication (p = 0.0042). Forgotten doses were the leading cause of nonadherence in HC patients (83%, as compared to 54% in the TT group), whereas dose reduction by the patient was higher in the TT group (32 vs. 17%). Conclusions: Despite advances in providing information to patients leading to better adherence among TT patients, efforts towards better patient education are warranted including dedicated staff for monitoring outpatient anticancer oral therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The participants recognized a need for greater education on adherence of treatment stakeholders, as also mentioned in recent publications. 14,25,44,81,82 Nurses who are strong patient advocates should also participate in adherence monitoring during the therapy. 83 If patients are ultimately accountable for adhering to their prescribed treatment, they can be supported through effective communication and partnership with their healthcare providers.…”

mentioning

confidence: 99%

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

et al. 2014

View full text Add to dashboard Cite

Correspondence: Lucien.Noens@uzgent.be BCR-ABL inhibitors for treating chronic myeloid leukemia in chronic phase have transformed a previously incurable malignancy into a manageable condition. However, suboptimal medication adherence has been observed with these agents affecting clinical outcomes and healthcare costs. In order to raise awareness of the problem of adherence, and before developing pragmatic strategies to enhance medication adherence, a deep understanding of the best approaches for measuring adherence in chronic myeloid leukemia patients and identifying non-adherence is required. A systematic literature review on the prevalence, measurement methods, consequences and risk factors for non-adherence to BCR-ABL inhibitors and adherence-enhancing interventions was performed and critically appraised. Of the 19 included articles, 9 were retrospective. Average adherence varied from 19% to almost 100% of the proportion of prescribed drug taken, but it was measured through various different methods and within different study groups. Suboptimal adherence was associated with a negative impact on both clinical and economic outcomes. There is a lack of supportive evidence demonstrating a difference in adherence across BCR-ABL inhibitors and even contradictory results between the 2 nd generation inhibitors. Drug-related adverse events and forgetfulness were common reasons for intentional and unintentional non-adherence, respectively, but further research is required to identify additional reasons behind non-adherence or patients at risk of non-adherence. Non-adherence in chronic myeloid leukemia patients treated with BCR-ABL inhibitors is common and associated with critical outcomes. However, this review highlights important existing gaps, reveals inconsistent definitions, and a lack of standardized methods for measuring adherence in chronic myeloid leukemia. All require further investigation. ABSTRACT © F e r r a t a S t o r t i F o u n d a t i o nAnalyses statement for systematic reviews. 16 Publication database (EMBASE, PubMed, and Cochrane Library) specific search terms consisted of both single and MeSH terms for the disease, adherence and BCR-ABL inhibitor therapy (Online Supplementary Table S1). The last search was conducted on December 20 th , 2011. Full-text references were provided for the eligible abstracts that were published after completion of the search process and the analyses. In addition, and due to the lack of existing evidence of adherence in CML, clinical and economic conference proceedings were also searched with a time limit of three years. Preliminary inclusion (or exclusion) of a specific study or conference abstract was based on review of the title and abstract by 2 independent reviewers against pre-specified criteria (Table 1). Final inclusion of the study was based on an in-depth review of the full manuscript. Multiple variables were extracted from the articles to answer study objectives (Online Supplementary Table S2). The analysis was descriptive only. Since abstracts in conference pr...

show abstract

“…One reason for this heterogeneity may be related to the treatment period when the data collection was performed, since the patient adherence to the treatment at the beginning is higher . Evidences suggest that adherence to imatinib decreases throughout treatment period (Marin et al, 2010;Gater et al, 2012).…”

Section: Resultsmentioning

confidence: 99%

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia

Alves

Lima

Nagai

et al. 2016

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia

Cited by 58 publications

References 36 publications

Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies

Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia

Contact Info

Product

Resources

About